Carboplatin & Paclitaxel With or Without Bevacizumab and/or Cetuximab in Advanced or Recurrent Non-Small Cell Lung Cancer
The purpose of this study is to compare how well treatment with carboplatin and paclitaxel with or without bevacizumab works with or without cetuximab as therapy for patients with stage IV or recurrent non-small cell lung cancer. The primary objective is to compare overall survival (up to 3 years) based on the different treatment used. The study will enroll 1,700 participants from many cancer centers in the US. In addition to other conditions for enrollment, eligible patients have newly diagnosed stage IV lung cancer or their lung cancer has recurred after prior surgery and/or radiation therapy. Study participants have not been previously treated with chemotherapy or bevacizumab.